Evidence map›Paper›PMID 42498786›Full record

ArticleNature communications2026

JN.1-adapted vaccination is associated with readjustment of ancestral memory B cells toward neutralization within the JN.1 antigenic space.

Metodi V Stankov, Matthias Bruhn, Markus Hoffmann, Abdus Salam, Amy Eichmann, Inga Nehlmeier, Luis A Manthey, Torsten Witte, Stefan Pöhlmann, Gerrit Ahrenstorf and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Metodi V Stankov *Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.ORCID 0000-0003-3001-2478
Matthias Bruhn *Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany.
Markus HoffmannInfection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany.ORCID 0000-0003-4603-7696
Abdus SalamInstitute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany.
Amy EichmannInfection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany.
Inga NehlmeierInfection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany.ORCID 0000-0002-8752-7491
Luis A MantheyDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Torsten WitteDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Stefan PöhlmannInfection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany.ORCID 0000-0001-6086-9136
Gerrit AhrenstorfDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Christine HappleDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Alexandra Dopfer-JablonkaDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-7129-100X
Ulrich KalinkeInstitute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany.ORCID 0000-0003-0503-9564
Georg M N BehrensDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. Behrens.georg@mh-hannover.de.ORCID 0000-0003-3111-621X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antigenic drift of SARS-CoV-2 toward the JN.1 lineage has prompted the development of variant-adapted COVID-19 booster vaccines. However, these boosters are thought to primarily recall pre-existing memory B cells (MBC), raising concerns about their ability to realign the immune response in highly pre-exposed populations. Here we analyze antibody and B cell responses in pre-exposed individuals (n = 42; median 4.5 prior COVID-19 vaccinations; 90% with at least one prior SARS-CoV-2 infection) following vaccination with a JN.1-adapted mRNA vaccine. Vaccination is associated with increased IgG binding and enhanced neutralization of JN.1 and related descendant variants. Longitudinal profiling of antigen-specific MBC shows that Wu01-only and Wu01/JN.1 cross-reactive cells remain dominant, while JN.1-only cells modestly increase by day 21. Single-cell RNA-sequencing of antigen-specific MBC in a representative sub-cohort (n = 7), combined with functional monoclonal antibody analyses, demonstrates that somatic hypermutation (SHM) drives intra-clonotype specialization toward improved JN.1 binding and neutralization. These findings indicate maturation of pre-existing, class-switched MBC rather than substantial de novo recruitment of naïve B cells. In conclusion, JN.1-adapted booster vaccination is associated with refinement of pre-existing MBC repertoires toward the JN.1 antigenic space and with enhanced neutralization of contemporary and antigenically proximate variants.

Indexed as

Antibodies, NeutralizingCOVID-19COVID-19 VaccinesMemory B CellsSARS-CoV-2Antibodies, ViralAntigens, ViralB-LymphocytesHumansImmunization, SecondaryImmunoglobulin GImmunologic MemorySomatic Hypermutation, ImmunoglobulinVaccinationAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCOVID-19 VaccinesImmunoglobulin G

Identifiers

PMID42498786
PMCPMC13400639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.